Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
(CRND TorCA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease, including Alzheimer's Disease (AD), Lewy Body Disease (LBD), Vascular Disease (VaD) and Frontotemporal lobar degeneration (FTLD).
Who Is on the Research Team?
Maria C Tartaglia, M.D.
Principal Investigator
Toronto Western Hospital, UHN; Tanz CRND
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo baseline assessments including brain imaging, body fluid samples, skin biopsy, cognitive ability, and behavioral questionnaires
Follow-up
Participants are monitored for changes in neurodegenerative protein levels, structural and functional brain differences, and cognitive phenotype
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor
Baycrest
Collaborator
Sunnybrook Health Sciences Centre
Collaborator
Centre for Addiction and Mental Health
Collaborator
University of Toronto
Collaborator
Toronto Dementia Research Alliance (TDRA)
Collaborator